Does Blue Cross Blue Shield Cover Jardiance (Empagliflozin)?

How BCBS Formulary Placement Works for Jardiance

Blue Cross Blue Shield is not a single insurer. It is a federation of 34 independent companies operating across all 50 states, plus the Federal Employee Program (FEP). Each affiliate maintains its own formulary, which means empagliflozin may sit on Tier 2 in one state and Tier 3 in another.

On most BCBS commercial PPO and HMO formularies reviewed for 2026, Jardiance appears as a preferred brand (Tier 2) or non-preferred brand (Tier 3). Tier 2 copays typically range from $30 to $60 per month, while Tier 3 copays can run $60 to $100 or require coinsurance of 25% to 50% after the deductible. The FEP Basic Option formulary has historically placed SGLT2 inhibitors in the preferred brand tier with a prior authorization flag 1.

Your specific cost depends on three variables: which BCBS affiliate writes your policy, whether you hold a commercial or Medicare Advantage plan, and whether your plan year has shifted empagliflozin between tiers during a mid-year formulary update. Call the number on the back of your BCBS card and ask the pharmacy benefits department which tier Jardiance occupies on your current formulary. That single call can save you hours of guesswork.

BCBS Medicare Advantage plans follow CMS formulary guidelines and frequently require both prior authorization and step therapy. Commercial plans have more flexibility. Some high-deductible health plans (HDHPs) paired with HSAs may require the full negotiated rate until the deductible is met, which can exceed $500 per fill at a retail pharmacy.

Prior Authorization Criteria for Jardiance on BCBS Plans

Most BCBS state affiliates require prior authorization before dispensing empagliflozin. The PA process confirms that the prescription aligns with the drug's FDA-approved labeling and that clinical criteria are met.

Standard PA criteria across BCBS affiliates typically include a confirmed diagnosis of type 2 diabetes mellitus, heart failure (NYHA class II-IV with reduced ejection fraction), or chronic kidney disease at risk of progression. For the type 2 diabetes indication, most plans want documentation that the patient has tried or has a contraindication to metformin. The prescriber must submit a recent HbA1c value (usually within 90 days) and confirm that the patient does not have type 1 diabetes or a history of diabetic ketoacidosis.

PA turnaround times vary. BCBS plans generally process standard requests within 72 hours and urgent requests within 24 hours, consistent with state insurance regulations. The prescriber's office handles submission, but patients should confirm within 48 hours that the request was actually sent. A common failure point: the PA form sits in a fax queue at the clinic and never reaches the insurer.

For heart failure, the PA may reference the EMPA-REG OUTCOME trial (N=7,020), which demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo in patients with type 2 diabetes and established cardiovascular disease. Cardiovascular death specifically fell by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) 1. This trial was the basis for the FDA's cardiovascular indication expansion and is the evidence BCBS medical directors cite when evaluating coverage for cardiac indications.

The EMPEROR-Reduced trial (N=3,730) further showed that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in patients with heart failure and reduced ejection fraction, regardless of diabetes status 2. If your prescriber cites both trials in the PA, approval rates improve.

Step Therapy Requirements on BCBS Plans

Step therapy (also called "fail first") means the insurer requires you to try a less expensive medication before it will authorize a costlier one. For empagliflozin, the most common step therapy requirement across BCBS affiliates is a documented trial of metformin lasting at least 90 days.

Some plans also require a trial of a generic sulfonylurea (glipizide, glimepiride) or a generic DPP-4 inhibitor before approving an SGLT2 inhibitor. This second step is less common but appears on certain BCBS Medicare Advantage and exchange-plan formularies.

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of HbA1c 3. When a patient meets these criteria, the ADA guideline essentially bypasses the rationale for step therapy. Prescribers should include this guideline citation in any step therapy exception request.

To request a step therapy override, the prescriber must document one of three things: the patient tried the required first-line agent and it failed (inadequate glycemic control, intolerable side effects), the patient has a medical contraindication to the step therapy drug (eGFR <30 mL/min for metformin, for example), or published guidelines recommend empagliflozin as a first-line option for the patient's specific clinical profile. BCBS plans are required under most state laws to offer a step therapy exception process, and the turnaround is generally 72 hours for a standard request.

The BCBS Federal Employee Program (FEP) and Jardiance

The BCBS Federal Employee Program covers approximately 5.3 million federal employees, retirees, and dependents. FEP operates a single national formulary, which simplifies matters compared to the state-affiliate patchwork.

On the 2025-2026 FEP formulary, empagliflozin is listed as a covered brand medication with prior authorization required. The FEP Basic Option copay for preferred brand drugs is typically $55 for a 30-day retail fill and $130 for a 90-day mail-order fill. FEP Standard Option costs run higher. FEP does not use step therapy for SGLT2 inhibitors in the same way that some state BCBS affiliates do, but the PA must confirm an on-label indication.

Federal employees should check the FEP formulary search tool at fepblue.org for the most current tier and PA status. The formulary updates annually, and mid-year changes are possible after CMS or FDA label modifications.

What Jardiance Costs with BCBS Insurance vs. Without

The manufacturer list price for Jardiance (empagliflozin 10 mg or 25 mg, 30 tablets) is approximately $680 per month. Without any insurance, cash-pay prices at retail pharmacies cluster around that same figure, though GoodRx-type discount cards may bring cash prices down to roughly $540 to $620 depending on the pharmacy.

With BCBS coverage, your out-of-pocket cost depends on the tier. Tier 2 placement on a commercial PPO typically yields a $35 to $50 copay. Tier 3 placement can mean $75 to $100 or 30% to 50% coinsurance. On a high-deductible plan, you may pay the full negotiated rate (often $400 to $550) until your deductible is met.

Boehringer Ingelheim, the manufacturer of Jardiance, offers a savings card for commercially insured patients that can reduce copays to as low as $10 per month, with a maximum annual benefit. This card cannot be used with government insurance (Medicare, Medicaid, Tricare, or VA benefits). Patients with BCBS commercial plans are generally eligible. The savings card stacks on top of your insurance benefit, meaning the manufacturer covers the difference between your copay and $10 4.

For patients on BCBS Medicare Advantage plans, Jardiance may qualify for Extra Help (Low Income Subsidy) through CMS if the patient meets income thresholds. The Medicare Part D coverage gap ("donut hole") was closed in 2025 under the Inflation Reduction Act, capping annual out-of-pocket drug costs at $2,000. This benefits patients taking Jardiance long-term.

How to Appeal a BCBS Denial of Jardiance

A denial is not the end. BCBS plans are required to offer at least one level of internal appeal, and most states mandate an external review option after the internal appeal is exhausted.

Start by reading the denial letter carefully. It will contain a specific reason code. The three most common denial reasons for empagliflozin are: step therapy not completed, prior authorization criteria not met (missing lab values or diagnosis documentation), and off-label use (weight loss is not an FDA-approved indication for empagliflozin).

For the internal appeal, the prescriber should submit a letter of medical necessity that includes the patient's diagnosis, relevant lab results (HbA1c, eGFR, BNP if heart failure), prior medication trials and outcomes, and citations to clinical guidelines supporting empagliflozin use. The ADA Standards of Care 3 and the ACC/AHA heart failure guidelines are the two most persuasive references. Include the EMPA-REG OUTCOME cardiovascular mortality data 1 and, if applicable, the EMPA-KIDNEY results showing a 28% reduction in the risk of kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64 to 0.82, P<0.001) 5.

BCBS internal appeals must be filed within 180 days of the denial in most states. The insurer has 30 days (standard) or 72 hours (expedited/urgent) to respond. If the internal appeal fails, you can request an independent external review through your state's insurance department. External reviewers overturn about 40% to 60% of pharmacy benefit denials when the prescriber provides strong clinical documentation, according to data from the National Association of Insurance Commissioners.

"The key to a successful appeal is matching the patient's clinical profile to published guideline recommendations and then citing the specific trial data that supports the drug's use for that profile," notes a 2023 summary from the American College of Cardiology on insurance navigation for guideline-directed medical therapy 6.

Empagliflozin for Weight Loss: Will BCBS Cover It?

Empagliflozin is not FDA-approved for weight loss. The drug does produce modest weight reduction as a secondary effect. In EMPA-REG OUTCOME, patients on empagliflozin lost approximately 2 kg more than those on placebo over 3.1 years of follow-up 1. This is far less than the 15% to 22% body weight reductions seen with GLP-1 receptor agonists like semaglutide or tirzepatide.

Most BCBS plans explicitly exclude coverage of medications prescribed solely for weight loss unless the drug carries an FDA-approved anti-obesity indication. If a prescriber writes empagliflozin with a primary diagnosis of obesity (ICD-10 E66.01), the claim will almost certainly be denied. However, if the patient has type 2 diabetes, heart failure, or CKD as a primary diagnosis and weight loss is a secondary benefit, the claim should process normally through the standard PA pathway.

Some BCBS affiliates have begun covering GLP-1 agonists for obesity under separate obesity benefit riders. Empagliflozin is unlikely to appear on those obesity-specific formularies because its weight loss effect is too modest to meet the clinical threshold for anti-obesity pharmacotherapy, which the Endocrine Society defines as at least 5% total body weight loss at 12 weeks 7.

Comparing Empagliflozin to Other SGLT2 Inhibitors on BCBS Formularies

BCBS formularies typically list multiple SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro). Formulary preference varies by affiliate and by the rebate agreements each plan negotiates with manufacturers.

If your BCBS plan places dapagliflozin on a lower tier than empagliflozin, switching may save money. The DELIVER trial (N=6,263) demonstrated that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 18% (HR 0.82, 95% CI 0.73 to 0.92, P<0.001) in heart failure with preserved ejection fraction 8. Both empagliflozin and dapagliflozin have comparable class-level evidence for type 2 diabetes, heart failure, and CKD.

Ask your prescriber whether a therapeutic substitution is clinically appropriate if tier placement or copay differences are significant. BCBS plans often allow pharmacist-initiated therapeutic interchange within the SGLT2 class if the prescriber consents.

Tips to Reduce Your Jardiance Costs on a BCBS Plan

Use mail-order pharmacy. BCBS plans typically charge 2 to 2.5 times the 30-day copay for a 90-day mail-order supply, saving roughly one month's copay per quarter. Request the manufacturer savings card from your prescriber or at jardiance.com if you hold a BCBS commercial plan. Ask your prescriber to submit the PA proactively at the time of prescribing rather than waiting for a pharmacy rejection, which adds 3 to 7 days. If your plan requires step therapy, ensure your medical record clearly documents prior metformin use, including start date, dose, duration, and reason for discontinuation.

"Patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease should receive an SGLT2 inhibitor with demonstrated benefit, independent of baseline HbA1c or the use of other glucose-lowering agents," states the ADA 2024 Standards of Care, Section 10 3. Print this recommendation and bring it to your prescriber's office to support any PA or appeal.

Patients who hit the Medicare Part D $2,000 annual out-of-pocket cap under the Inflation Reduction Act will pay $0 for Jardiance for the remainder of the calendar year once that threshold is reached.